Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
To establish the maximum tolerated dose (MTD) of INCB007839 given as multiple doses for 28
days and to determine if a higher MTD can be established when INCB007839 is administered in
combination with prophylactic anticoagulation and with a 2 and a half day (5 doses) treatment
interruption every two weeks.